| Biomarker ID | 267 |
| PMID | 18446232 |
| Year | 2008 |
| Biomarker | Methylation Status of SLC16A12 |
| Biomarker Basis | Methylation Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated (9% normal vs 22% in Cancerous condition) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- MYO3A human kinase ARCHS4 coexpression,RPS6KA3 human kinase ARCHS4 coexpression |
| Experiment | prostate cancer Vs normal prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 20 patients with Tumors were compared to 20 normal patients to study methylation in this study. |
| Senstivity | 55% |
| Specificity | 95% |
| AUC | NA |
| Accuracy | 90% |
| Level Of Significance | p<0.05 |
| Method Used | methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SLC16A12 |